0.445
-0.22 (-33.23%)
| Penutupan Terdahulu | 0.667 |
| Jumlah Dagangan | 1,068,474 |
| Harga / Jualan (P/S) | 0.060 |
| Harga / Buku (P/B) | 0.130 |
| Julat 52 Minggu |
| Margin Keuntungan | -13.88% |
| Margin Operasi (TTM) | -14.56% |
| EPS Cair (TTM) | -5.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.12% |
| Nisbah Semasa (MRQ) | 4.25 |
| Aliran Tunai Operasi (OCF TTM) | -11.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.60 M |
| Pulangan Atas Aset (ROA TTM) | -11.78% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Sunshine Biopharma Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.17% |
| % Dimiliki oleh Institusi | 1.74% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |